Although it does not generally infect humans, a single mutation of the H5N1 virus in the highly pathogenic avian and bovine clade 2.3.4.4b could overcome this barrier and possibly trigger a pandemic. Scientists at The Scripps Research Institute have warned of this possibility after studying the three-dimensional structure of the viral hemagglutinin and seeing how a change in one amino acid would make it more suitable for the human cell receptor. The researchers stress the need to monitor new mutations of this virus in order to act quickly in case the global jump to our species occurs. Read More
In a recently published study, researchers from Taipei Medical University and collaborators have reported on their efforts to discover new DYRK1A-specific inhibitors. Read More
Researchers from Janssen Research & Development LLC presented preclinical data for JNJ-87801493, a first-in-class CD20 targeted CD28 costimulatory bispecific antibody (Ab), currently in early clinical development for the treatment of B-cell malignancies. Read More
Base Therapeutics (Shanghai) Co. Ltd.’s NK-510 cell injection, a zero-off-target base-edited natural killer (NK) cell product, has received approvals to start clinical trials from both the U.S. FDA and China’s NMPA for clinical trials for advanced solid tumors. Read More
In a recent publication, researchers from Colorado State University presented the development and evaluation of humanized mice as a hybrid dual-use model for testing therapeutics against both HIV and SIV infections.
Scientists at Beigene Ltd. and Beigene Switzerland GmbH have identified phosphatidylinositol 3-kinase α (PI3Kα) (H1047R mutant) inhibitors reported to be useful for the treatment of cancer, congenital lipomatous overgrowth, vascular malformations, epidermal naevi and skeletal abnormalities and PIK3CA related overgrowth spectrum (PROS). Read More
Medigene AG has announced the selection of KRAS G12V, in the context of HLA*A11, as the initial target for the co-development of T-cell receptor-guided T-cell engagers (TCR-TCEs) with Wuxi Biologics Co. Ltd. Read More
Researchers from the University of Connecticut have worked in the development of a collection of propargyl-linked antifolate (PLA) chemotypes for infectious pathogens with different functionalities, including potential anti-cancer, anti-inflammatory and anti-infection activities. Read More
Recludix Pharma Inc. has divulged proteolysis targeting chimeras (PROTACs) comprising cereblon (CRBN) ligands coupled to a signal transducer and activator of transcription 3 (STAT3) targeting moiety via a linker acting as STAT3 degradation inducers reported to be useful for the treatment of cancer and inflammatory disorders. Read More
Researchers have described the development of a novel murine model of glioblastoma established with a patient-derived xenograft (PDX) in humanized mice that harbored an almost complete human immune microenvironment. Read More
Researchers at Inventisbio Co. Ltd. and Inventisbio LLC have described Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer. Read More
